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Abstract 
Background: Plasmodium falciparum has shown multidrug resistance, leading to the necessity for the development 
of new drugs with novel targets, such as the synthesis of isoprenic precursors, which are excellent targets because the 
pathway is different in several steps when compared with the human host. Naphthoquinone derivatives have been 
described as potentially promising for the development of anti‑malarial leader molecules. In view of that, the focus 
in this work is twofold: first, evaluate the in vitro naphthoquinone antiplasmodial activity and cytotoxicity; secondly, 
investigate one possible action mechanism of two derivatives of hydroxy‑naphthoquinones.
Results: The two hydroxy‑naphthoquinones derivatives have been tested against P. falciparum in vitro, using 
strains of parasites chloroquine‑sensitive (3D7) and chloroquine‑resistant (Dd2), causing 50% inhibition of parasite 
growth with concentrations that varied from 7 to 44.5 μM. The cell viability in vitro against RAW Cell Line displayed 
 IC50 = 483.5 and 714.9 μM, whereas, in primary culture tests using murine macrophages,  IC50 were 315.8 and 532.6 μM 
for the two selected compounds, causing no haemolysis at the doses tested. The in vivo acute toxicity assays exhib‑
ited a significant safety margin indicated by a lack of systemic and behavioural toxicity up to 300 mg/kg. It is sug‑
gested that this drug seems to inhibit the biosynthesis of isoprenic compounds, particularly the menaquinone and 
tocopherol.
Conclusions: These derivatives have a high potential for the development of new anti‑malarial drugs since they 
showed low toxicity associated to a satisfactory antiplasmodial activity and possible inhibition of a metabolic pathway 
distinct from the pathways found in the mammalian host.
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Background
Malaria still remains a major parasitic disease in the 
tropical and subtropical regions of the world due to its 
economic impact and high morbidity. In 2015, accord-
ing to the latest estimates from the World Health 
Organization (WHO), there were 214 million new cases 
resulting in 438,000 deaths, mostly children under 
5 years of age [1]. Although several anti-malarials drugs 
are available, their efficacies are limited by the existence 
of drug-resistant parasites worldwide (including Bra-
zil), especially in the case of Plasmodium falciparum 
[2, 3]. In this context, it is needed either the discovery 
of new drugs associated with new targets or to improve 
determined anti-malarial drug class.
The antiparasitic activity of hydroxy-naphthoqui-
nones derivatives is already known, with studies con-
firming its efficacy against Leishmania braziliensis 
and Leishmania amazonensis [4], Trypanosoma cruzi 
[5] and P. falciparum [6–10]. Its mechanism of action 
was already proposed by means of the inhibition of the 
mitochondrial electron carrier chain [11].
The biosynthesis of isoprenoids pathway in P. falci-
parum are excellent therapeutic targets because they 
are different or even absent in the human host. Their 
many functions are quite important for the parasite’s 
survival [12]. Vitamins E and K, belonging to the fam-
ily of isoprenoid, has an isoprenic chainsaw from MEP 
pathway. These vitamins are essential components for 
the cellular machinery found in all organisms. The 
menaquinone (MQ) (vitamin  K2) is employed as elec-
tron carriers required for the mitochondrial respiratory 
chain [13–15], with the α-tocopherol (TC) represent-
ing more bioactivity of vitamin E, protecting the mem-
branes against peroxidation [16].
According to the Resolution CNS 251/97, pre-clinical 
research is the first step in the study on the develop-
ment of new drugs. This approach should provide infor-
mation for possible therapeutic application, besides to 
predict some risks such as toxicity and adverse effects 
[17]. The absorption, distribution, metabolism, and 
elimination (ADME) characteristics of a drug are con-
ventionally viewed as an important part of the drug 
development [18]. Unfavourable ADME is the leading 
cause of costly and clinical failures in the development 
of new chemical products during the drug develop-
ment projects [19–21]. It is believed that around 
40–50% of study in clinical phases fail due to toxicity 
and pharmacokinetic difficulties [18, 22]. Therefore, 
there is an increasing interest in the early ADME pre-
diction of drug candidates. Besides of drug-likeness 
and ADME data predictions, it has been demonstrated 
that the anti-malarial activity and interference with the 
synthesis of isoprenic precursors of three derivatives of 
hydroxy-naphthoquinones against P. falciparum.
Methods
Compounds
The tested hydroxy-naphthoquinone derivatives were set-
ting in the School of Pharmaceutical Sciences of Ribeirão 
Preto, University of São Paulo, Brazil [9], namely: 2-ani-
line-3-hydroxy-1,4-naphthoquinone, 2-chloro-aniline-3- 
hydroxy-1,4-naphthoquinone, 4-methoxy-aniline-3-hy-
droxy-1,4-naphthoquinone and 2.6-dimethyl-aniline-3- 
hydroxy-1.4-naphthoquinone, from now on designated as 
4a–4d, respectively. Compounds 4a and 4c were selected 
for all tests since they are soluble in the solution with a 
maximum of 1% DMSO, presenting satisfactory results in 
the screening tests.
Drug‑likeness and ADME predictions
In drug discovery projects, the fastest efficient method 
to guide the evaluation of the drug-like properties of 
compound libraries is to apply simple rules that com-
pare their physicochemical properties with those pre-
sented by existing drugs with suitable pharmacokinetic 
profile [23]. To do that, we applied the Lipinski’s rule 
of five (R05), Lead-like soft, Drug-like soft, REOS and 
ZINC rules in compounds 4a and 4c using FAF-Drugs3 
web-server [24]. It was also used the MarvinSketch Ver-
sion 5.0 (http://www.chema xon.com) [25] and ALOGPS 
2.1 [26] software programs to determine the following 
descriptors (structural and physicochemical properties): 
molecular weight (MW), numbers of hydrogen bond 
donors (HBD), hydrogen bond acceptors (HBA), num-
ber of rotatable and rigid bonds, flexibility, number of 
carbon/hetero-atoms, value of ratio Het/c (H/C ratio), 
number/maximum size of rings, number of atoms with 
a net charge, sum of formal charges, carbon bond satu-
ration (Fsp3), number of STEREOCENTRES, molecular 
polarizability, molar refractivity, polar surface area (PSA), 
octanol/water partition coefficient (logP), octanol–water 
distribution coefficient (logD) and aqueous solubility 
(logSw). Afterwards, an oral absorption/bioavailability 
evaluation considering Lipinski was performed, Veber, 
Egan, and Bayer (Bayer Oral Physchem Score) rules. 
Finally, we run ADME by PreADME program [27].
Plasmodium falciparum cultures
Experiments were performed using chloroquine-sensi-
tive 3D7 and chloroquine-resistant Dd2 strains. Para-
sites were cultured using the method of Trager and 
Jensen, with previously described modifications [28]. 
Synchronized ring phase cultures were obtained by two 
consecutive treatments at intervals of 48  h with a 5% 
(m/v) solution of D-sorbitol (Sigma-Aldrich) [29]. All 
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tests described below were performed in triplicate and 
repeated at least three times.
Antiplasmodial activity
Drugs were diluted with 0.1% DMSO, followed by a serial 
1:2 dilution (nine concentrations) ranging from 160 to 
0.6  µM in the complete culture medium. Anti-malarial 
activity was performed using SYBR Green I assay [30] in 
96-well culture plate where the compounds were added 
to the culture of P. falciparum with predominantly rings 
of 1% parasitaemia and 3% haematocrit. The micro-
plate was incubated at 37  °C for 48  h under an atmos-
phere having a low oxygen level (5%  CO2). Chloroquine 
was used as a control, in standard concentrations. After 
48  h of incubation, cells infected with 3D7 and Dd2 
strains were analysed using the SYBR Green I. Values of 
 IC50 were calculated using GraphPad PRISM software. 
Compounds were ranked, according to its activity, as 
being high activity  (IC50 ≤ 10  µg/ml); moderate activity 
(10 < IC50 < 100 µg/ml); and low activity  (IC50 > 100 µg/ml) 
[31].
Treatment com hydroxy‑naphthoquinones and metabolic 
labelling
Synchronous cultures of P. falciparum with 10% para-
sitaemia of schizonts were treated with 6.5  µM and 
3.75  µM, for 4a and 4c, respectively, corresponding to 
80% of  IC50. A flask was kept untreated and is considered 
the positive control. After 36  h, the culture was labeled 
with [1-(n)-3H]GGPP (3.125  µCi/ml) in normal RPMI 
1640 medium [32] during the last 16  h. The schizonts 
were purified by magnetic column (MACS Separation 
Columns “CS”, Miltenyi Biotec) [33]. The parasitaemia 
was estimated by microscopic examination of Giemsa-
stained smears and the volume was adjusted of purified 
culture, according to the control, so that equal numbers 
of treated and untreated parasites were applied. After 
metabolic labelling and purification, lyophilized schiz-
onts were used for extraction of MQ and TC. The final 
extract was injected into the HPLC-RT [34].
Reversed‑phase high‑performance liquid chromatography 
(RP‑HPLC)
The molecules of MQ and TC were purified by an iso-
cratic system with mobile phase methanol: ethanol (50:50 
v/v), flow 0.5  ml/min and detection performed by UV 
absorption spectrum at a wavelength equal to 270  nm. 
The mobile phase was filtered on a PTFE (solvent A) and 
NYLON (solvent B) membrane of 0.20  µM. Radioactive 
fractions were dried by evaporation at 24  °C and resus-
pended in scintillation fluid. Quantification of the radio-
activity (c.p.m.) was performed on the device Beckman 
5000 β-radiation scintillation counter (Beckman, CA, 
USA) [34].
Statistical analyses
The  IC50 was estimated by linear interpolation as com-
pared to the drug-free controls, using the software 
GraphPad PRISM software. Comparative statistical anal-
ysis of the peak areas from HPLC chromatograms of sam-
ples treated with compounds 4a and 4c versus untreated 
samples were performed for ANOVA, (95% confidence 
interval), using the statistical software program Assistat 
7.7 beta [35]. The results were considered statistically sig-
nificant at P-value ≤ 0.05.
Results
All physicochemical descriptors and ADME predictions 
calculated for compound 4a and 4c are shown in Table 1. 
Figure 1 depicts the PhysChem filters positioning of can-
didates in (a) Lipinski RO5  [36], (b) Lead-like soft, (c) 
Drug-like soft, (d) REOS and (e) ZINC rules designed by 
Table 1 Physicochemical descriptors and  ADME-related 






Rotatable bonds 2 3
Rigid bonds 19 19
Flexibility 0.10 0.14
Carbon atoms 16 17
Hetero atoms 4 5
H/C ratio 0.25 0.29
Ring 2 2
Max size ring 10 10
Total charge 0 0
Fsp3 0.00 0.06
Stereo centres 0 0
Polarizability  (cm2/V) 28.17 30.70
Refractivity  (m3/mol) 78.11 84.57
PSA (Å2) 66.4 75.63
logP 3.24 3.21
logD 1.88 1.72
logSw − 3.68 − 3.75
HIA (%) 93.67 93.85
Caco2 (nm/s) 20.20 21.55
MDCK (nm/s) 343.27 208.47
logKp − 3.59 − 3.60
BBB (C. brain/C. blood) 0.63 0.07
PPB (%) 86.91 85.73
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combining several drugs’ physicochemical parameters. 
The R05 and Veber rules area obtained with the follow-
ing descriptors ranges: logP (− 2 to 5), molecular weight 
(150 to 500), tPSA (20 to 150), rotatable bonds (0 to 10), 
H-bonds acceptors (0 to 10) and donors (0 to 5). The 
complexity, permeability/metabolic stability (Golden Tri-
angle Rule), oral absorption estimation and the oral bioa-
vailability evaluation of compounds are showed in Fig. 2.  
The  IC50 for 4a and 4c were determined by in  vitro 
growth inhibition assay using P. falciparum 3D7 and Dd2 
strains. Table  2 and Fig.  3 present the mean IC50 val-
ues for 4a, 4c, and chloroquine (reference anti-malarial 
drug).
Change in MQ and TC biosynthesis resulting from 
treatment with the hydroxy-naphthoquinone derivatives 
is shown in Fig. 4. The activity (in c.p.m.) of the fractions 
corresponding to the retention times of MQ 15 and TC 
16 were compared with those of the corresponding frac-
tions from untreated controls. Biosynthesis of MQ and 
TC were inhibited in 71.2% and 62.7% (58.1% and 49.6%) 
by derivative 4a (4c).
Discussion
Due to the global spread of the multidrug-resistant P. fal-
ciparum to usual anti-malarials, the disease control has 
been hampered mainly in African and Asian countries, 
by means of the development of new anti-malarial drugs 
and the search for new therapeutic targets. However, for 
a new drug to be released to the custom market, numer-
ous studies are required to prove its safety and efficacy. 
The first step is the pre-clinical in silico, in  vitro and 
in vivo tests, depicting the relevance of the findings, the 
possible therapeutic applications as well as previewing 
some risks with its use.
The physicochemical property filters are used in drug 
discovery and drug development to narrow down the 
scope of molecules  [37, 38]. They estimate the drug-
likeness profile (Druglikeness prediction) of the active 
compounds by considering their physical and chemical 
properties  [39–41]. After analysing the physicochemical 
descriptors values calculated, it was observed that the 
components 4a and 4c meet the criteria for the Lipinski’s 
R05, Lead-like soft, Drug-like soft, REOS and ZINC rules 
[42] (see Table 1 and Fig. 1).
Figure  2 shows that both compounds reach the crite-
ria for the number of system ring, stereocentres, rotat-
able and rigid bonds, as well as the maximum size of 
the system rings (number of system ring, stereocentres, 
rotatable and rigid bonds, the flexibility and the maxi-
mum size of system rings) successfully [43]. In this study, 
compound values are superimposed on a database com-
prising currently 1790 chemical structures of drugs [44]. 
By Golden Triangle Rule, both compounds have an opti-
mal permeability (low clearance) and a good metabolic 
stability. They are believed to be the designed drug from 
the most ligand and lipophilic efficient lead into the cen-
tre of the Golden Triangle and should provide the maxi-
mum potency, stability, and permeability [45].
To further estimate the druggability of these naphtho-
quinones derivatives were report their ADME descriptors 
and profiles and potential biological activities using an in 
silico approach are depicted in Table 1. While the likeli-
hood of drug absorption has been described in compli-
ance to the Ro5, Veber rule, human intestinal absorption 
(HIA), skin permeability (logKp), colorectal carcinoma 
(Caco2) and Madin-Darby canine kidney (MDCK) cells 
permeability, the drug distribution was modeled using 
the blood/brain partition coefficient (BBB) and the coef-
ficient of binding to human serum albumin (PPB).
Human skin has a low permeability for most of the for-
eign substances, which are unable to penetrate and dif-
fuse through the skin. Pre ADME predicts in  vitro skin 
permeability and the result value is given as logKp (per-
meability coefficient). In this work, the compounds 4a 
and 4c show logkp de − 3.59 e − 3.69 respectively, delim-
ited within the scale of − 8 to − 1, common drug 95% 
[46]. As a comparative test, the water, for example, has 
predicted ranging from logkp − 7.39 to − 6.27 [47].
The oral absorption evaluation is one of the most influ-
ential ADME characteristics in the early stages of lead 
discovery and optimization [48]. The compounds 4a and 
4c are well absorbed in the human intestine, with values 
for HIA being 93.67% and 93.85% respectively. The per-
meability coefficient in human intestinal epithelial (Caco-
2) and renal (MDCK) cell presented intermediate values 
for 4a (4c), lying within the recommended ranges of 95% 
for known drugs [49–51].
The RO5 and Veber rules comprise a set of rules that 
attempt to predict if a molecule could be administered 
orally [52]. As can be seen in Fig. 1, compounds 4a and 
4c fail within R05 and Veber rules area obtained with 
the analyzed descriptors. In addition, the compounds 
examined successfully meet the proposed criteria for 
Egan et  al. [53] and Lobell et  al. [54], which states that 
for a compound be transcellularly absorbed from the 
gastrointestinal tract into systemic circulation it must be 
Fig. 1 Radar plots positioning compounds values within the selected filter ranges (pale blue and red). The blue line of compound values should fall 
within the a Lipinski RO5, b Lead‑like soft, c Drug‑like soft, d REOS and e ZINC filter area bounded by the light blue line
(See figure on next page.)
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reasonably soluble in aqueous solution, although should 
not be too polar (PSA), too lipophilic (CLOGP), too large 
(MW) or too flexible (rotatable bonds) to pass cellular 
membranes.
A good oral bioavailability reduces the amount of an 
administered drug necessary to achieve a desired phar-
macological effect and, therefore, could reduce the risk of 
side-effects and toxicity. A compound positioning within 
466 and 916 orally bioavailable compounds extracted 
from the DrugBank and e-Drug3D databases respectively 
[43, 55] are presented in a graph obtained by applying 
the PCA (Principal Component Analysis) of the 15 main 
physicochemical descriptors of these molecules.
The plasma protein binding (PPB) and blood–brain 
barrier (BBB) penetration [56, 57] were calculated for 
detecting its distribution into the human body. The PPB 
values obtained for 4a and 4c indicate that the chemi-
cals are moderately bound to albumin. An analysis of 
the PPB’s percentage distribution among some thera-
peutic drugs showed that chemotherapeutics presenting 
PPB > 90% binding can be classified as therapeutic drugs 
[58]. Further, a BBB penetration value determined in this 
work indicates a middle (low) absorption to central nerv-
ous system-CNS by studied molecules [59]. This is cru-
cial in the pharmaceutical sphere because CNS-active 
compounds must pass across it, while CNS-inactive com-
pounds do not, in order to avoid any CNS side effects.
According to the System Biopharmaceutics Classifica-
tion (BCS), which ranks drugs based on their aqueous 
solubility and intestinal permeability through the corre-
lation between in vitro dissolution and bioavailability of 
the drug in vivo [60, 61], atovaquone is classified in class 
II, which includes drugs with low solubility, having high 
permeability and good absorption [62].
Atovaquone, as well as the tested compounds, is a 
3-substituted-2-hydroxy-1.4-naphthoquinone complex. 
It presents an excellent anti-malarial activity but has poor 
pharmacological properties, such as low bioavailability 
and high binding to plasma proteins due to its lipid solu-
bility [63]. To improve its bioavailability, some analogs of 
atovaquone were created whose changes were made in 
the naftoquinoidal group, especially the alkyl side chain. 
It is known that modification of this chain can alter 
the activity of the drug [64]. The 4a and 4c compounds 
tested in  vivo [9] presented interesting antiplasmodial 
activity, using the  murine Plasmodium berghei model. 
The output of these experiments may result in low bio-
availability and/or high plasma protein binding, and 
atovaquone. The low bioavailability of atovaquone, and 
probably of our compounds, is due to the limited solubil-
ity in aqueous media, although conferring good intestinal 
permeability. Tests that include solubility enhancement 
techniques through physical changes, chemical or by 
various methods has been not only already studied, but 
also be employed, since approximately 70% of new drug 
candidates and more than 40% of the newly developed 
chemical formulas in the pharmaceutical industry are 
practically insoluble in water [65, 66].
The antiplasmodial in  vitro activity of derivatives 
hydroxy-naphthoquinones was satisfactory against the 
3D7 strain (sensitive chloroquine), being classified as 
high activity anti-malarial compounds. For the Dd2 strain 
(multidrug resistant), the  IC50 values were fivefold higher; 
being classified as moderately active against this strain.
In a study which tested over 10 modified molecules 
from hydroxy-naphthoquinones, the  IC50 values were 
greater than 50.0 μM [8]. Another study tested five deriv-
atives hydroxy-naphthoquinone with radical aquil, and 
only in one of the derivatives, whose radical was a phenyl 
grouping, was very active in the nanomolar order of mag-
nitude [67]. Derivatives of 1.4-naphthoquinones, which 
was a radical trifluormethylbenzene, showed  IC50 in the 
nanomolar order of magnitude. This high anti-malarial 
activity is probably due to the instability of the radical 
trifluormethylbenzene, which leads to the formation of 
free radicals that are toxic to the parasite [11]. However, 
a study with three derivatives hydroxy-naphthoquinone 
aminated, showed that only one was effective against 
the P. falciparum NF54; strain sensitive to most anti-
malarials [7]. Their radical was a phenylpiperazine on 
carbon 6, with the same root added to other lead com-
pounds. This demonstrates antiplasmodial effectiveness 
in these other changes, confirming a relationship with 
this radical activity. The phenylpiperazine is attached to 
a piperazine phenylaniline, showing similarity with radi-
cals used in structural changes, as in the present study, 
which is aniline derivatives and associated with the effec-
tiveness of that radical. In another study, eight deriva-
tives of 2-hydroxy-3-methylamino-1.4-naphthoquinone 
were tested, and five were active, exhibiting  IC50 values 
less than 30 μM against P. falciparum W2 (chloroquine-
resistant strain) [10].
(See figure on next page.)
Fig. 2 Graphical reports of compounds 4a and 4c. a Compound values (blue line) superimposed on an oral library with min and max ranges 
(pink and red) during a compound complexity analysis. b Golden Triangle Rule evaluation: compounds located in the yellow triangle are likely to 
have an optimal permeability and a good metabolic stability. c For an oral absorption evaluation, compound values (blue line) should fall within 
RO5 and Veber rules area (light green line). d The Oral Property Space, obtained by applying a Principal Component Analysis of the 15 principal 
physicochemical descriptors of user’s compound (red), compared to two oral sub‑libraries extracted from eDrugs (blue) and DrugBank (orange)
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Pyrimethamine, an anti-malarial already used in com-
bination with sulfadoxine, has a higher  IC50 when com-
pared to present work and narrow therapeutic window 
[68], confirming the importance of obtained results. Sev-
eral studies have shown that the structural changes in the 
molecule have reduced its cytotoxic effect while improv-
ing either the biological activity [69, 70] or the pharma-
cokinetic and pharmacodynamic properties [69].
Concerning the likely target of the derivatives of 
hydroxy-naphthoquinones tested, the results obtained 
Table 2 The  IC50 mean for 4a and 4c compounds and chloroquine
IC50 (inhibitory concentration 50%); high  activity
a  (IC50 ≤ 10 μg/ml); moderate  activityb (10 < IC50 < 100 μg/ml) (Meneguetti et al. [31])
P. falciparum 4a 4c Chloroquine
Mean  IC50 (μg/ml) Variance Mean  IC50 (μg/ml) Variance Mean  IC50 (μg/ml) Variance
3D7 strain 2.99a 2.41–3.57 2.06a 1.47–2.65 0.012a 0.007–0.017
Dd2 strain 11.79b 10.36–13.22 10.10b 7.72–12.48 0.15a 0.12–0.18
Fig. 3 Dose–response curve of 4a and 4c compounds on P. falciparum 3D7 and Dd2 strains infected erythrocytes. Values are mean ± SEM in 
representative experiment in triplicate. E1, E2 and E3 are repeats of the tests
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in this study suggest the biosynthesis of isoprenoids as 
a possible target, since the two products of this path-
way had a significantly decreased production: the vita-
min  K2 (MQ) that act as an important electron receiver 
of the respiratory chain [34] and the α-tocopherol that 
protects membranes from lipid peroxidation [32]. The 
α-tocopherol also acts as an antioxidant and free-rad-
ical scavenger, can efficiently quench  O2 and scavenge 
various radicals released during oxidative stress [71]. 
A candidate for an anti-malarial drug that acts simul-
taneously in the synthesis of these two molecules is 
interesting because it can trick the parasite resistance 
mechanism, both interfering in the cellular respiration 
when in plasma membrane integrity. Furthermore, due 
to its absence in humans, the MEP pathway can be con-
sidered as an important drug target for malaria, although 
additional studies should be performed to confirm which 
enzyme is inhibited, after the addition of isopentenyl-PP 
[12] or geranylgeranyl pyrophosphate synthase (GGPP) 
to the cultures [72]. Due to their structural similarity 
with atovaquone, these novel compounds may probably 
act through a similar mechanism. Atovaquone is believed 
to inhibit electron flow in aerobic respiration, by binding 
to cytochrome b in place of ubiquinone in the parasite 
mitochondria. Such inhibition hampers the activity of 
dihydroorotate dehydrogenase, an enzyme linked to the 
mitochondrial electron transport system that is required 
in the de novo synthesis of pyrimidines [73]. Addition-
ally, the redox potential of hydroxy-naphthoquinones is 
suggested to cause an oxidative stress which may also be 
responsible for some antiparasitic activity of this class 
of compounds. However, one recent study found that 
3-[4-(trifluoromethyl)benzyl]-menadione do not inhibit 
the mitochondrial electron transport chain, but exert 
their anti-malarial activity as redox-active subversive 
substrates [11].
The compound 4c presents better in vitro results, since 
it has the lowest  IC50 and interfered in the biosynthesis of 
the two products of the isoprenoid pathway. In this sense, 
it provides a better activity of the compound, prevent-
ing escape mechanisms by the host avoiding the oxida-
tive stress process, despite as much as tocopherol acts as 
an antioxidant. In silico computations have been carried 
out for the calculation of the physicochemical and sub-
sequent drug-likeness and ADME predictions. Satisfy-
ing a number of rules and physicochemical filter (see 
“Methods”), the compounds present acceptable drug-like 
profile, specifically structural alerts, good oral bioavaila-
bility, permeability, and distribution. Modifications in the 
structure of compound 4c as the salt formation and com-
plexation with β-cyclodextrin can be interesting because 
solubility enhancing techniques can promote the efficacy 
of the compound leading to an increase in bioavailability 
as a consequence of improved solubility.
Conclusions
Thus, the molecules tested in the present study, although 
presenting lower anti-malarial activity than some of the 
usual class of anti-malarials, could be used as prototypes 
for future programmes that could develop safe and effec-
tive drugs using their pharmacophores with those of 
other drugs into synergistic conjugates.
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